Conversion to everolimus monotherapy in maintenance liver transplantation: Feasibility, safety, and impact on renal function

Transplant International

Volumn 22, Issue 3, 2009, Pages 279-286

  De Simone, Paolo ^a   Carrai, Paola ^a   Precisi, Arianna ^a   Petruccelli, Stefania ^a   Baldoni, Lidiana ^a   Balzano, Emanuele ^a   Ducci, Juri ^a   Caneschi, Francesco ^b   Coletti, Laura ^a   Campani, Daniela ^a   Filipponi, Franco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Calcineurin inhibitors; Everolimus; Immunosuppression; Liver transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; EVEROLIMUS; STEROID; TACROLIMUS; VIRUS RNA;

ACNE; ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FEASIBILITY STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; MOUTH ABSCESS; MOUTH ULCER; OUTCOME ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PRURITUS; PSORIASIS; SEX RATIO; SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA;

EID: 59249098555     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00768.x     Document Type: Article

References (30)

1. Calne RY. Immunosuppression in liver transplantation. NEJM 1994 331 : 1154.
2. Ojo A. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007 27 : 498.
3. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000 13 : 313.
4. Mells G, Neuberger J. Reducing the risk of cardiovascular disease in liver allograft recipients. Transplantation 2007 83 : 1141.
5. Marchetti P. New-onset diabetes mellitus after liver transplantation: from pathogenesis to management. Liver Transpl 2005 11 : 612.
6. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin-inhibitor free immunosuppression in kidney transplantation. Transpl Int 2005 20 : 813.
7. Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006 26 : 201.
8. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000 69 : 307.
9. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007 39 : 2937.
10. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997 64 : 32.
11. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat transplantation: a study of the efficacy and pharmacokinetics of rapamycine derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyslosporine. J Heart Lung Transplant 1999 18 : 150.
12. Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001 71 : 160.
13. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006 12 : 1640.
14. Treeck O, Wacwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006 102 : 292.
15. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007 13 : 4261.
16. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octeotride and the mTOR inhibitor RAD001 (Everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008 87 (3 168.
17. Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007 84 : 786.
18. Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000 6 : 734.
19. Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002 16 (Suppl. 7 49.
20. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnig KH. Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003 16 : 504.
21. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003 9 : 126.
22. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003 9 : 1079.
23. Morard I, Dumortier J, Spahr L, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007 13 : 658.
24. Yang YJ, Li LX, He Q, et al. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related insufficiency after liver transplantation. Hepatobiliary Pancreat Dis Int 2007 6 : 376.
25. Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipient with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007 83 : 1389.
26. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007 13 : 1694.
27. Cejas N, Casciato P, Descalzi V, et al. Conversion from calcineurin inhibitors (CNIs) to sirolimus (SRL) immunosuppression is beneficial in liver transplant (LT) recipients with renal dysfunction (RD) [abstract]. Liver Transpl 2007 13 (Suppl. 1 113.
28. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31.
29. Levin N, Eknoyan G, Pipp M, Staeinberg E. National Kidney Foundation: Dialysis Outcome Quality Initiative-Development of methodology for practice guidelines. Nephrol Dial Transplant 1997 12 : 2060.
30. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997 25 : 658.